<unk> , sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD). It is given by intravenous infusion.<unk>  prevents complement-enhanced activation of autoimmune human B cells in vitro. This drug is being developed by Bioverativ, a Sanofi company.<unk>  was approved for medical use in the United States in February 2022.
Sutimlimab
Donanemab
Tafasitamab
Lepra 
Naxitamab
Sargramostim
Tebentafusp
Titermax